DSP 3905
Alternative Names: ANP-390; DSP-3905Latest Information Update: 02 Feb 2024
At a glance
- Originator Sunovion Pharmaceuticals
- Class Analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 25 Oct 2023 Sumitomo Pharma completes a phase I trial in Neuropathic pain in USA
- 25 Oct 2023 AlphaNavi Pharma exercises option regarding DSP 3905 under development for Neuropathic pain by Sumitomo Pharma
- 27 Jul 2023 Phase I development in Neuropathic pain is still ongoing in USA (PO) (Sumitomo Dainippon Pharma's pipeline, July 2023)